Cargando…
Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility
BACKGROUND: The role of the gut microbiome in arresting pathogen colonization and growth is important for protection against Clostridium difficile infection (CDI). Observational studies associate proton pump inhibitor (PPI) use and CDI incidence. We hypothesized that PPI use affected the distal gut...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242847/ https://www.ncbi.nlm.nih.gov/pubmed/25426290 http://dx.doi.org/10.1186/2049-2618-2-42 |
_version_ | 1782346020398563328 |
---|---|
author | Seto, Charlie T Jeraldo, Patricio Orenstein, Robert Chia, Nicholas DiBaise, John K |
author_facet | Seto, Charlie T Jeraldo, Patricio Orenstein, Robert Chia, Nicholas DiBaise, John K |
author_sort | Seto, Charlie T |
collection | PubMed |
description | BACKGROUND: The role of the gut microbiome in arresting pathogen colonization and growth is important for protection against Clostridium difficile infection (CDI). Observational studies associate proton pump inhibitor (PPI) use and CDI incidence. We hypothesized that PPI use affected the distal gut microbiome over time, an effect that would be best explored by time-longitudinal study of healthy subjects on PPI in comparison to treatment-naïve CDI subjects. This study enrolled nine healthy human subjects and five subjects with treatment-naïve CDI. After random assignment to a low (20 mg/day) or high (2× 20 mg/day) dose group, fecal samples were collected from the nine healthy subjects before, during, and after 28 days of PPI use. This was done in conjunction with pre-treatment fecal collection from CDI subjects. High-throughput sequencing (16S rRNA) was performed on time-longitudinal samples to assess changes to the healthy gut microbiome associated with prolonged PPI usage. The healthy samples were then compared to the CDI subjects to explore changes over time to the gut microbiome associated with PPI use and potentially related to CDI. RESULTS: We report that PPI usage at low and high dosages, administered for 28 days, resulted in decreases to observed operational taxonomic unit (OTU) counts after both 1 week and 1 month. This decrease resulted in observed OTU levels that were similar to those found in treatment-naïve CDI patients, which was partly reversible after a 1 month recovery period. We did not detect a dose-dependent difference in OTU levels nor did we detect significant changes in taxa previously reported to be affected by PPI treatment. CONCLUSION: While our observation of diminishing observed OTU counts during PPI therapy is a preliminary finding in a small cohort, our hypothesis that PPIs disrupt the healthy human gut microbiome is supported in this group. We conclude that decreases in observed species counts were reversible after cessation of PPI usage within 1 month. This finding may be a potential explanation for the association between prolonged PPI usage and CDI incidence. |
format | Online Article Text |
id | pubmed-4242847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42428472014-11-25 Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility Seto, Charlie T Jeraldo, Patricio Orenstein, Robert Chia, Nicholas DiBaise, John K Microbiome Research BACKGROUND: The role of the gut microbiome in arresting pathogen colonization and growth is important for protection against Clostridium difficile infection (CDI). Observational studies associate proton pump inhibitor (PPI) use and CDI incidence. We hypothesized that PPI use affected the distal gut microbiome over time, an effect that would be best explored by time-longitudinal study of healthy subjects on PPI in comparison to treatment-naïve CDI subjects. This study enrolled nine healthy human subjects and five subjects with treatment-naïve CDI. After random assignment to a low (20 mg/day) or high (2× 20 mg/day) dose group, fecal samples were collected from the nine healthy subjects before, during, and after 28 days of PPI use. This was done in conjunction with pre-treatment fecal collection from CDI subjects. High-throughput sequencing (16S rRNA) was performed on time-longitudinal samples to assess changes to the healthy gut microbiome associated with prolonged PPI usage. The healthy samples were then compared to the CDI subjects to explore changes over time to the gut microbiome associated with PPI use and potentially related to CDI. RESULTS: We report that PPI usage at low and high dosages, administered for 28 days, resulted in decreases to observed operational taxonomic unit (OTU) counts after both 1 week and 1 month. This decrease resulted in observed OTU levels that were similar to those found in treatment-naïve CDI patients, which was partly reversible after a 1 month recovery period. We did not detect a dose-dependent difference in OTU levels nor did we detect significant changes in taxa previously reported to be affected by PPI treatment. CONCLUSION: While our observation of diminishing observed OTU counts during PPI therapy is a preliminary finding in a small cohort, our hypothesis that PPIs disrupt the healthy human gut microbiome is supported in this group. We conclude that decreases in observed species counts were reversible after cessation of PPI usage within 1 month. This finding may be a potential explanation for the association between prolonged PPI usage and CDI incidence. BioMed Central 2014-11-25 /pmc/articles/PMC4242847/ /pubmed/25426290 http://dx.doi.org/10.1186/2049-2618-2-42 Text en Copyright © 2014 Seto et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Seto, Charlie T Jeraldo, Patricio Orenstein, Robert Chia, Nicholas DiBaise, John K Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility |
title | Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility |
title_full | Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility |
title_fullStr | Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility |
title_full_unstemmed | Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility |
title_short | Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility |
title_sort | prolonged use of a proton pump inhibitor reduces microbial diversity: implications for clostridium difficile susceptibility |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242847/ https://www.ncbi.nlm.nih.gov/pubmed/25426290 http://dx.doi.org/10.1186/2049-2618-2-42 |
work_keys_str_mv | AT setocharliet prolongeduseofaprotonpumpinhibitorreducesmicrobialdiversityimplicationsforclostridiumdifficilesusceptibility AT jeraldopatricio prolongeduseofaprotonpumpinhibitorreducesmicrobialdiversityimplicationsforclostridiumdifficilesusceptibility AT orensteinrobert prolongeduseofaprotonpumpinhibitorreducesmicrobialdiversityimplicationsforclostridiumdifficilesusceptibility AT chianicholas prolongeduseofaprotonpumpinhibitorreducesmicrobialdiversityimplicationsforclostridiumdifficilesusceptibility AT dibaisejohnk prolongeduseofaprotonpumpinhibitorreducesmicrobialdiversityimplicationsforclostridiumdifficilesusceptibility |